Enhanced immunogenicity elicited by a novel DNA vaccine encoding the SARS-CoV-2 S1 protein fused to the optimized flagellin of Salmonella typhimurium in mice
Microbiology Spectrum · 12.12.2023 · 11 (6)
DOI: 10.1128/spectrum.02549-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology Spectrum, erschienen am 12.12.2023. Verfasst von Li Song und 7 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Key Laboratory of Zoonosis, Yangzhou University , Yangzhou, Jiangsu, China. Hauptthemen laut MEDLINE: Vaccines, DNA, COVID-19. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China (NKPs), National Natural Science Foundation of China (NSFC), China Postdoctoral Science Foundation (China Postdoctoral Foundation Project).
Abstract (Originalsprache)
The development of safe and efficient vaccines against coronavirus disease 2019 (COVID-19) is necessary for global public health. The spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a major target for the COVID-19 vaccines. Among the available vaccine types, DNA vaccines are a promising alternative to conventional vaccines. Here, we developed a novel DNA vaccine containing the SARS-CoV-2 S1 subunit and an optimized flagellin adjuvant (FliCΔD2D3) from Salmonella typhimurium . The S1 gene and S1- fliC ΔD2D3 fusion gene were codon optimized and then cloned into the antibiotic-resistance-gene-free vector asd -pVAX1, producing asd -pVAX1-S1 and asd -pVAX1-S1- fliC ΔD2D3, respectively. The expression of S1 and S1-FliCΔD2D3 proteins was confirmed after transient expression in HEK293T cells. After in vitro characterization of the vaccine candidates, we evaluated the humoral and cellular immune responses induced in BALB/c mice. The DNA vaccine induced a long-lasting humoral response for approximately 4 months, and the elicited serum antibodies efficiently blocked the binding of the SARS-CoV-2 S1 receptor-binding domain to its entry receptor (angiotensin-converting enzyme 2). Moreover, the DNA vaccine induced strong Th1/Th2-mixed immune responses, as demonstrated by the similar levels of S1-specific immunoglobulin (Ig) G1 and IgG2a in the serum and the significantly elevated Th1-type (IFN-γ and TNF-α) and Th2-type (IL-4 and IL-6) cytokine expression from splenic lymphocytes. Importantly, asd -pVAX1-S1- fliC ΔD2D3 immunization in mice could significantly enhance the levels of immune responses compared to asd -pVAX1-S1. This study provides crucial information regarding the selection of a safer DNA vector and a new adjuvant for the vaccine development of SARS-CoV-2 and other infectious diseases. IMPORTANCE The development of safe and effective vaccines is needed to control the transmission of coronavirus disease 2019 (COVID-19). Synthetic DNA vaccines represent a promising platform in response to such outbreaks. Here, DNA vaccine candidates were developed using an optimized antibiotic-resistance gene-free asd-pVAX1 vector. An optimized flagellin (FliC) adjuvant was designed by fusion expression to increase the immunogenicity of the S1 antigen. S1 and S1-FliCΔD2D3 proteins were strongly expressed in mammalian cells. The FliCΔD2D3-adjuvanted DNA vaccine induced Th1/Th2-mixed immune responses and high titers of neutralizing antibodies. This study provides crucial information regarding the selection of a safer DNA vector and adjuvant for vaccine development. Our FliCΔD2D3-adjuvanted S1 DNA vaccine is more potent at inducing both humoral and cellular immune responses than S1 alone. This finding provides a new idea for the development of novel DNA vaccines against COVID-19 and could be further applied for the development of other vaccines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jiangsu Key Laboratory of Zoonosis, Yangzhou University , Yangzhou, Jiangsu, China.
- Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou University , Yangzhou, Jiangsu, China.
- Key Laboratory of Prevention and Control of Biological Hazard Factors (Animal Origin) for Agrifood Safety and Quality, Ministry of Agriculture of China, Yangzhou University , Yangzhou, Jiangsu, China.
ORCID-Profile: Xinan Jiao, Zhiming Pan
Förderung
- National Key Research and Development Program of China (NKPs)
- National Natural Science Foundation of China (NSFC)
- China Postdoctoral Science Foundation (China Postdoctoral Foundation Project)
- Key Research and Development Program (Modern Agriculture) Project of Jiangsu Province
- 111 Project
- Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)
Zitieren
APA
Song, L., Wang, Q., Wen, Y., Tan, R., Cui, Y., Xiong, D., Jiao, X., & Pan, Z. (2023). Enhanced immunogenicity elicited by a novel DNA vaccine encoding the SARS-CoV-2 S1 protein fused to the optimized flagellin of Salmonella typhimurium in mice. Microbiology Spectrum. https://doi.org/10.1128/spectrum.02549-23
Vancouver
Song L, Wang Q, Wen Y, Tan R, Cui Y, Xiong D, et al. Enhanced immunogenicity elicited by a novel DNA vaccine encoding the SARS-CoV-2 S1 protein fused to the optimized flagellin of Salmonella typhimurium in mice. Microbiology Spectrum. 2023. doi:10.1128/spectrum.02549-23
BibTeX
@article{Song2023,
author = {Song, Li and Wang, Qiaoju and Wen, Yaya and Tan, Ruimeng and Cui, Yaodan and Xiong, Dan and Jiao, Xinan and Pan, Zhiming},
title = {Enhanced immunogenicity elicited by a novel DNA vaccine encoding the SARS-CoV-2 S1 protein fused to the optimized flagellin of Salmonella typhimurium in mice},
journal = {Microbiology Spectrum},
year = {2023},
doi = {10.1128/spectrum.02549-23}
}
EUVIMED